文献速递肿瘤 PET/CT核素与放射性配体治疗

复发前列腺癌患者的68Ga-PSMA、68Ga-FAPI-04与18F-FDG PET/CT表现

68Ga-PSMA and 68Ga-FAPI-04 PET/CT Findings With 18F-FDG PET/CT in a Patient With Recurrent Prostate Cancer.
PubMed 文献 · Clin Nucl Med · 2023-01-10

一例79岁前列腺癌患者化疗期间前列腺特异性抗原升高,接受68Ga-PSMA、68Ga-FAPI-04和18F-FDG PET/CT检查。FDG在左侧前列腺及膀胱壁肿瘤区域摄取异常,而PSMA和FAPI在相应区域无活性或较低。经尿道肿瘤切除后疾病进展,再次行68Ga-PSMA和18F-FDG PET/CT,本例证实前列腺癌存在个体内肿瘤异质性。

要点

  • FDG在左侧前列腺及膀胱壁肿瘤区域摄取异常,PSMA和FAPI在相应区域无活性或较低。
  • 经尿道肿瘤切除后疾病进展,再次行68Ga-PSMA和18F-FDG PET/CT。
  • 本例证实前列腺癌存在个体内肿瘤异质性,经3种不同放射性药物PET/CT显像。

核心结论

  • 本例证实前列腺癌存在个体内肿瘤异质性,经3种不同放射性药物PET/CT显像。

研究设计与样本

  • 病例报告:一例79岁前列腺癌患者,化疗期间前列腺特异性抗原升高,接受68Ga-PSMA、68Ga-FAPI-04和18F-FDG PET/CT检查。

主要发现

  • FDG在左侧前列腺及膀胱壁肿瘤区域摄取异常,而PSMA和FAPI在相应肿瘤区域无活性或较低。
  • 经尿道肿瘤切除后疾病进展,再次行68Ga-PSMA和18F-FDG PET/CT。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 79-year-old man with prostate cancer was evaluated with 68Ga-prostate-specific membrane antigen (PSMA), 68Ga-FAPI-04, and 18F-FDG PET/CT scans since a rise in prostate-specific antigen was seen at last control while receiving chemotherapy. Abnormal FDG uptakes were observed in the tumoral areas of the left half of the prostate and walls of the bladder, although PSMA and FAPI activity were absent or lower in the relevant tumoral areas. Restaging 68Ga-PSMA and 18F-FDG PET/CT scans were obtained on the patient whose progression continued after transurethral tumor resection. Herein, we present a case proving intraindividual tumor heterogeneity in prostate cancer underwent PET/CT imaging with 3 different radiopharmaceuticals.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Tatar G, Ergül N, Baloğlu MC, et al. 68Ga-PSMA and 68Ga-FAPI-04 PET/CT Findings With 18F-FDG PET/CT in a Patient With Recurrent Prostate Cancer. Clin Nucl Med. 2023. PMID: 36723899. doi:10.1097/RLU.0000000000004522

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。